News Headline Summary
Johnson & Johnson (JNJ) failed to warn vaginal mesh risk, lawyer tells jury
- First case of 1,800 in vaginal mesh trial.
Reaction details (09:24)
- No immediate reaction in JNJ shares, last trade at USD 72.70 (+0.66%).
Analysis details (09:25)
- The trial relates to a vaginal mesh implant in a case brought by a South Dakota woman who blames the product for constant pain and 18 subsequent operations.
10 Jan 2013 - 09:22
Subscribe Now to RANsquawk
Click here for a 1 week free trial
RANsquawk provides audio news and commentary for over 15,000
professional traders and brokers worldwide. Services include:
Real-time audio coverage from 0630 to 2200 London time plus Asia-Pac 2200 to 1000 London time
Teams of analysts covering equities, fixed income, FX, energy, and metals markets
Real-time scrolling news service with instant analysis
Daily and weekly pre-market research and calendars
Video updates covering near-term key risk events & primary trading themes
One-to-one chat with our expert analysts